secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2024-03-29T23:59:59+00:00
Accession:  0001104659-24-041148
Event type: other
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx reprices CEO Sumit Aggarwal's options to $0.90 from $37.47 per share
--------------------------------------------------------------------------

- Option repricing approved by Board on March 25, 2024 for CEO Sumit Aggarwal.
- Exercise price reduced to $0.90 per share (closing price on March 25, 2024).
- Affects 196,880 shares previously exercisable at weighted average $37.47.
- All outstanding eligible options under 2018 Equity Incentive Plan included.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465924041148/0001104659-24-041148-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465924041148/tm248887d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-041148

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer